Author

Renda H. Ferrari

Observed name: Renda Ferrari

Observed institution: Takeda Oncology (United States)

OpenAlex ID: A5079422802

Ixazomib for the treatment of multiple myeloma

2018 · Paul G. Richardson, Sonja Zweegman, et al. · Expert Opinion on Pharmacotherapy · 61

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

2019 · Vania T.M. Hungria, Hans C. Lee, et al. · Blood · 19

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

2020 · Sudhir Manda, Habte A. Yimer, et al. · Clinical Lymphoma Myeloma & Leukemia · 15

Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

2022 · Michael A. Thompson, Mario Boccadoro, et al. · Clinical Lymphoma Myeloma & Leukemia · 11

P-208: Ongoing trials investigating in-class transition (iCT) from parenteral to oral proteasome inhibitor (PI)-based treatment with ixazomib in multiple myeloma (MM)

2021 · Stephen Noga, Hans Lee, et al. · Clinical Lymphoma Myeloma & Leukemia

Multiple myeloma (MM) vaccination (influenza, FV and pneumococcal, PV) rates worldwide and impact on infection, hospitalization, and death.

2020 · Michael A. Thompson, Caitlin Costello, et al. · Journal of Clinical Oncology

A tale of two paradigms: fixed duration vs continuous therapy in routine clinical practice: An INSIGHT MM study analysis of duration of therapy

2019 · Katja Weisel, Vania Hungria, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 7

Citation count: 106

H-index: 4

I10-index: 4